Drug Dosing Considerations in Alternative Hemodialysis

Slides:



Advertisements
Similar presentations
Clinical Pharmacokinetic Equations and Calculations
Advertisements

Lecture 2 Clearance, maintenance dose and AUC
Pharmacogenetics and future drug development and delivery
Chronic Pain in End-Stage Renal Disease
Scared to the Marrow: Pitfalls and Pearls in Renal Imaging
The Pharmacokinetics of Intradialytic Administration of Eculizumab in an Infant  Ji Lee, PharmD, Peace Imani, MD, Jessica Geer, C-PNP, Michael Braun, MD,
Renal Tubular Acidosis and the Nephrology Teaching Paradigm
Sheldon Chen  Advances in Chronic Kidney Disease 
End-stage renal disease in developing countries
Manjunath P. Pai  Advances in Chronic Kidney Disease 
Regional Differences in the Associations Between Prescribed Dialysate Sodium Concentration and Interdialytic Weight Gain in the Dialysis Outcomes and.
Rosa K. Hand, MS, RDN, LD, Jerrilynn D. Burrowes, PhD, RD, CDN 
MyPlate for Healthy Eating With Chronic Kidney Disease (MyPlate Education for Patients With Chronic Kidney Disease Receiving Hemodialysis and Peritoneal.
Volume 65, Issue 2, Pages (February 2004)
Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006
Volume 85, Issue 6, Pages (June 2014)
Determinants of Plasma Adiponectin Levels in Nondiabetic Subjects With Moderate to Severe Chronic Kidney Disease  Luis F. Ramos, MD, Ayumi Shintani, PhD,
Janeen B. León, MS, RD, LD, Catherine M
Ciprofloxacin Pharmacokinetics in Critically Ill Patients Receiving Concomitant Continuous Venovenous Hemodialysis  Matthew S. Shotwell, PhD, Phillip.
Bone Disease in Elderly Individuals With CKD
Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective  J. Michael Lazarus, MD, Raymond M. Hakim,
An Update on Neurocritical Care for the Patient With Kidney Disease
Peter A. McCullough, MD, MPH  Advances in Chronic Kidney Disease 
Chronic Pain in End-Stage Renal Disease
Focusing on Health Literacy Might Help Us Cross the Quality Chasm
Janeen B. León, MS, RD, LD, Catherine M
Wayne Trebbin, MD, Peter Monteleone, MD 
Salt and Hypertension American Journal of Kidney Diseases
Nutritional Considerations for Dialysis Vegetarian Patients, Part One
Nutritional Considerations for Dialysis Vegetarian Patients, Part Two
The ESRD Uninsured Matter
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel.
Set Theory: Nephrology ∩ Urology
Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road  Eduardo Lacson, MD, MPH, Franklin Maddux, MD 
Iain C. Macdougall, MD  American Journal of Kidney Diseases 
Volume 91, Issue 5, Pages (May 2017)
Gentamicin pharmacokinetics during slow daily home hemodialysis
Pharmacokinetics of Multiple-Dose Levofloxacin in Hemodialysis Patients  Shuichi Tsuruoka, MD, PhD, Noritsugu Yokota, MD, PhD, Tokie Hayasaka, RN, Tetsuo.
A Role for Bromine Deficiency in Sleep Disturbances of Long-Term Dialysis Patients  Caterina Canavese, MD, Ester De Costanzi, MD, Piero Stratta, MD, Enrico.
Kidney-Friendly Label Reading for Chronic Kidney Disease Shoppers
Jeffrey Perl, MD, FRCP(C), Christopher T. Chan, MD, FRCP(C) 
Resolved: The Case for CKD Clinics
Dialysate Sodium: Choosing the Optimal Hemodialysis Bath
The Kidney Effects of Hematopoietic Stem Cell Transplantation
A Fundamental Theorem of Telehealth
Dmytro Khadzhynov, MD, Christian Joukhadar, MD, Harm Peters, MD 
Daniel L. Landry, DO, FASN  Advances in Chronic Kidney Disease 
Crossing Vessel and Crossroads With Urology
Current Concepts in Hemodialysis Vascular Access Infections
Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies  Charuhas V. Thakar, MD  American Journal.
Kim Dao, MD, Haithem Chtioui, MD, Yimin Lu, MD, Cody J
The Guitar-Maker: Model Education
Removal of Dabigatran by Hemodialysis
Hector J. Rodriguez, Regina Domenici, Anne Diroll, Irina Goykhman 
Volume 80, Issue 10, Pages (November 2011)
Confounding factors in the assessment of delivered hemodialysis dose
Internet Organ Solicitation, Explained
Patient Safety Issues in CKD: Core Curriculum 2015
Novel Strategies for Immune Monitoring in Kidney Transplant Recipients
Nocturia and Aging: Diagnosis and Treatment
How to Manage Functional Vitamin K Deficiency in CKD
Taqumpay Esmiraldo Tigcal Sacamay, W. Kline Bolton 
Lipoprotein abnormalities in diabetic nephropathy
Clinical Practice Recommendations For Peritoneal Dialysis Adequacy
Emergence of the Concept of Acute Kidney Injury
The timing of gentamicin administration affects the concentration-time profile in patients using hemodialysis. The timing of gentamicin administration.
Maristela Böhlke, PhD  American Journal of Kidney Diseases 
Clinical Practice Guidelines for Peritoneal Dialysis Adequacy
The Importance of Sodium Restrictions in Chronic Kidney Disease
Presentation transcript:

Drug Dosing Considerations in Alternative Hemodialysis Brian S. Decker, Bruce A. Mueller, Kevin M. Sowinski  Advances in Chronic Kidney Disease  Volume 14, Issue 3, Pages e17-e26 (July 2007) DOI: 10.1053/j.ackd.2007.03.004 Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Schematic representation of a 2-compartment open-pharmacokinetic model in concert with drug removal by hemodialysis. Drugs are assumed to be removed from the central compartment either by hemodialysis or through endogenous means. Abbreviations: Cc, concentration of drug in the central compartment; Cp, concentration of drug in the peripheral compartment; Vc, volume of distribution of drug in the central compartment; Vp, volume of distribution of drug in the peripheral compartment; Cls, systemic clearance (sum of all endogenous clearances, such as renal and nonrenal clearance); ClDist, distribution clearance or intercompartmental clearance; Cldial, dialytic clearance. During hemodialysis, the hatched line is “turned on” with an indicator variable, in the absence of hemodialysis the hatched line is turned off. Advances in Chronic Kidney Disease 2007 14, e17-e26DOI: (10.1053/j.ackd.2007.03.004) Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Levofloxacin (A), gentamicin (B), and vancomycin (C) concentration-time profiles for the central (plasma) compartment in regimens A, B, and C (see Table 2 for dosing regimens). The profiles are shown for the intradialytic and interdialytic periods for 1 week after the administration of the first drug dose. Regimen A is conventional hemodialysis administered 3 times weekly for 4 hours each session. The times for the dialysis session were 44 to 48, 92 to 96, and 164 to 168 hours. Regimens B and C were daily hemodialysis administered 6 times weekly for 2 hours each session. The times for the dialysis session were 22 to 24, 46 to 48, 70 to 72, 94 to 96, 118 to 120, and 142 to 144 hours. Abbreviations: Vc, volume of distribution of drug in the central compartment; Vp, volume of distribution of drug in the peripheral compartment; Cls, systemic clearance; ClDist, distribution clearance or intercompartmental clearance; Cldial, dialytic clearance.24-26 All drugs were infused immediately after hemodialysis, according to manufacturer’s recommendations. Levofloxacin and vancomycin were administered as an intravenous infusion over 1 hour; gentamicin was administered as an intravenous infusion over 30 minutes. Abbreviations: LD, loading dose; MD, maintenance dose; HD, hemodialysis Conventional dialysis: regimen A, hemodialysis administered 3 times weekly at 44 to 48, 92 to 96, and 164 to 168 hours. Daily hemodialysis: regimens B and C, hemodialysis administered 6 times weekly at 22 to 24, 46 to 48, 70 to 72, 94 to 96, 118 to 120, and 142 to 144 hours. Advances in Chronic Kidney Disease 2007 14, e17-e26DOI: (10.1053/j.ackd.2007.03.004) Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions